Showing 2631-2640 of 3980 results for "".
New Products
https://practicaldermatology.com/columns/new-products/new-products/21262/The Molecular Era in Melanoma Treatment
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-molecular-era-in-melanoma-treatment/21296/Melanoma Treatment Landscape Evolves
https://practicaldermatology.com/topics/skin-cancer-photoprotection/melanoma-treatment-landscape-evolves/21314/The first agent to target the PD-1 pathway, pembrolizumab may prolong life expectancy in some patients.Analyzing Risk Factors for Subsequent Primary Melanomas
https://practicaldermatology.com/topics/skin-cancer-photoprotection/analyzing-risk-factors-for-subsequent-primary-melanomas/21429/SPF Recommendations: Should They Change?
https://practicaldermatology.com/topics/skin-cancer-photoprotection/spf-recommendations-should-they-change/21475/What is the minimum SPF dermatologists should be recommending to their patients?Charging Toward Stage 2 of Meaningful Use
https://practicaldermatology.com/topics/practice-management/charging-toward-stage-2-of-meaningful-use/21467/As the next stage of the Federal EHR incentive program is set to begin, the forecast remains uncertain.New Products and Pharmacologic Developments
https://practicaldermatology.com/columns/new-products/new-products-and-pharmacologic-developments/21633/Therapeutic Review: A Host of New Treatments Emerged in 2018
https://practicaldermatology.com/topics/psoriasis/therapeutic-review-a-host-of-new-treatments-emerged-in-2018/20381/Here's a handy reference to new drugs and devices—and other key developments—this year.Advanced Management Solutions for High-Grade Cutaneous Toxicities to Cancer Therapy
https://practicaldermatology.com/topics/skin-cancer-photoprotection/advanced-management-solutions-for-high-grade-cutaneous-toxicities-to-cancer-therapy/57176/The emergence of immune checkpoint inhibitors (ICIs) has fundamentally altered the prognosis for patients with advanced skin malignancies, yet the high incidence of cutaneous immune-related adverse events (irAEs) remains a significant barrier to treatment continuity. Here, we review the clinical manHappy Patients, Happy Practice
https://practicaldermatology.com/topics/practice-management/happy-patients-happy-practice/21138/Six tips for effectively dealing with conflict.